Key result
The CaSR A/G genotype was more frequent in chronic hemodialysis patients with cardiac valvular calcification compared to those without (42.9% vs. 15%, P=0.050).
Why the study?
Is there an association between calcium-sensing receptor (CaSR) gene polymorphisms and cardiac valvular calcification in chronic hemodialysis patients?
Observational (n=41)
Is there an association between calcium-sensing receptor (CaSR) gene polymorphisms and cardiac valvular calcification in chronic hemodialysis patients?
Absolute Event Rate: 42.9% vs 15%
p-value: p=0.050
This pilot study found a borderline association between the CaSR A/G genotype and cardiac valvular calcification in chronic hemodialysis patients, highlighting the need for larger studies.
Borderline CaSR A/G association with valvular calcification in hemodialysis should not change practice; leaves open hypothesis for larger validation studies.
Cardiac valvular calcification (VC) is a frequent finding in chronic hemodialysis patients. In addition to demographic and metabolic factors, genetic susceptibility may also influence the occurrence and severity of these abnormalities and account for interindividual variability among patients. In this report, we studied the relation of calcium-sensing receptor (CaSR) gene polymorphisms to the development of VC in chronic hemodialysis patients. A total of 41 chronic hemodialysis patients (26 male, mean age 47.23 +/- 11.36 years vs. 15 females, mean age 48.13 +/- 14.66 years) undergoing treatment for more than 1 year were evaluated with transthoracic echocardiography. In patients with and without VC, CaSR gene polymorphisms (A990G, C1011G) were investigated by PCR, using allele-specific primers. In randomly chosen subjects, PCR analysis was verified by DNA sequencing. Cardiac valve calcification was detected in 21 patients (51.2%). Five of these patients (12.2%) had mitral valve calcification, 4 (9.75%) had aortic valve calcification, and 12 (29.27%) had both. In patients with VC, the frequency of the A/G genotype was slightly higher than those with no VC with a borderline P value (42.9% vs. 15%, chi(2)=3.840, P=0.050). The frequency of the C/C genotype was similar in patients with and without VC (90.5% vs. 85%, P>0.05). The results of this study are not enough to prove the role of CaSR gene polymorphisms in the development of VC. There is a need for large-scale studies on this topic.
No takes yet. Share an insight, caveat, or question.
Türkmen et al. (2009) conducted an observational in Chronic renal failure (n=41). Calcium-sensing receptor (CaSR) gene polymorphisms (A990G, C1011G) vs. Patients without cardiac valvular calcification was evaluated on Frequency of the A/G genotype in patients with vs without cardiac valvular calcification (p=0.050). The CaSR A/G genotype was more frequent in chronic hemodialysis patients with cardiac valvular calcification compared to those without (42.9% vs. 15%, P=0.050).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: